On November 3rd, at the "Witness the Birth of 'Nanochips', Embrace the Future of 'Nanopores' | New - Generation Gene Technology Innovation and Development Industry Forum", Suzhou Linaxin officially launched China's first solid - state nanopore life science tool — the "Lsmart - SP1 Detector", which attracted widespread attention in the industry. At the thematic forum held concurrently, participants from the capital market, investment institutions, technical teams and application experts gathered to discuss the opportunities and challenges in the solid - state nanopore track.

As a committed investor in Suzhou Linaxin, He Dinglin, Deputy General Manager of New Silk Road Capital, emphasized that the continuous investment in Linaxin stems from its systematic breakthroughs across the entire industrial chain of materials, devices, and algorithms, as well as the team’s solid engineering capabilities. He believes that Linaxin is capable of forging its own path in gene detection equipment.

Jiang Tengfei, Executive Director of Frost & Sullivan Consulting, pointed out that the IPO activity of global nanopore sequencing companies has increased significantly. Particularly, solid-state nanopores, with advantages in stability and integration, are emerging as new favorites among capital, and domestic enterprises are expected to achieve corner overtaking amid the wave of domestic substitution.

Hong Yang, Founder of Zhiyin Capital, stated that although the overall investment environment is tightening, solid-state nanopore projects with underlying technological innovation and clinical implementation capabilities still attract great attention. He suggested that enterprises should focus on segmented scenarios and build technological barriers.

Professor Zhu Libo from Wannan Medical College noted that Linaxin has conquered core challenges such as ultra-thin film preparation and low-noise signal detection, and is advancing wafer-level mass production processes. With the goal of achieving an annual production capacity of 1,000 units by 2026, this will lay a solid foundation for the next phase of industrialization.

Dr. Yang Haiping, R&D Director of Linaxin, said that the product will first focus on clinical scenarios such as rapid detection of pathogenic microorganisms and screening of tumor markers, and then expand into synthetic biology and basic scientific research fields.

Experts call on Linaxin to strengthen collaboration with hospitals and scientific research institutions, accelerate clinical validation and standard formulation, and adhere to underlying innovation. With the launch of its first product, Linaxin is emerging as a pioneer in domestic solid-state nanopore sequencing, taking a crucial step toward breaking foreign technological monopolies and building an independent life science tool ecosystem.